InflaRx N.V.IFRXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in the development of novel anti-inflammatory therapies targeting the complement C5a pathway. Its pipeline addresses unmet medical needs for severe inflammatory diseases including autoimmune and rare inflammatory disorders, serving global patient populations.
IFRX Q3 FY2025 Key Financial Metrics
Revenue
$25.7K
Gross Profit
$25.4K
Operating Profit
N/A
Net Profit
N/A
Gross Margin
98.6%
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
InflaRx N.V. Q3 FY2025 Financial Summary
InflaRx N.V. reported revenue of $25.7K for Q3 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $360.
Key Financial Metrics
| Total Revenue | $25.7K |
|---|---|
| Net Profit | N/A |
| Gross Margin | 98.6% |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
InflaRx N.V. Quarterly Revenue & Net Profit History
InflaRx N.V. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $25.7K | — | N/A | N/A |
| Q2 FY2025 | $42.6K | +520.3% | $-15.6M | -36559.8% |
| Q2 FY2024 | $6.9K | — | $-15.0M | -217803.1% |
Income Statement
| Q2 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Revenue | $6866 | $42587 | $25736 |
| YoY Growth | N/A | 520.3% | N/A |
Balance Sheet
| Q2 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Assets | $100.5M | $79.3M | N/A |
| Liabilities | $11.8M | $17.7M | N/A |
| Equity | $88.7M | $61.6M | N/A |
Cash Flow
| Q2 2024 | Q3 2025 | |
|---|---|---|
| Operating CF | $-29.2M | $-33.1M |